Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial.
about
Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Enzalutamide in castration-res ...... ntrolled phase 3 AFFIRM trial.
@en
Enzalutamide in castration-res ...... ntrolled phase 3 AFFIRM trial.
@nl
type
label
Enzalutamide in castration-res ...... ntrolled phase 3 AFFIRM trial.
@en
Enzalutamide in castration-res ...... ntrolled phase 3 AFFIRM trial.
@nl
prefLabel
Enzalutamide in castration-res ...... ntrolled phase 3 AFFIRM trial.
@en
Enzalutamide in castration-res ...... ntrolled phase 3 AFFIRM trial.
@nl
P2093
P2860
P356
P1433
P1476
Enzalutamide in castration-res ...... ntrolled phase 3 AFFIRM trial.
@en
P2093
David Forer
Howard I Scher
Johann S de Bono
Mohammad Hirmand
Yohann Loriot
P2860
P304
P356
10.1002/CNCR.30336
P407
P50
P577
2016-09-20T00:00:00Z